A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

Completed · Phase 2 · Has a placebo group

Conditions studied: Nocturia

In brief

The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in adults

Key facts

Study ID

NCT03201419

Run by

Ferring Pharmaceuticals

People needed

302

Starts

2017-07-27

Expected to finish

2019-10-31

Last updated by the study team

2022-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥18 years of age (at the time of written consent)
• Medical history of, or subject reported nocturia symptoms during the 6 months prior to Visit 1
• ≥2 nocturnal voids (an average over 3 days) as documented in the 3-day e-Diary prior to Visit 2
• The largest single voided volume must be ≥200 mL (at least 1 void ≥200 mL) as documented in the 3-day e-Diary prior to Visit 2
• Nocturnal polyuria, defined as Nocturnal Polyuria index >33%, a ratio of Nocturnal Urine Volume in excess of 33% of total daily (24-hour) urine volume as documented in the 3-day e-Diary prior to Visit 2
• ≥20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit 2) as documented in the 3-day e-Diary prior to Visit 3

You may not qualify if…

• Current diagnosis of Obstructive Sleep Apnoea (OSA)
• Restless Legs Syndrome (RLS)
• Bladder Outlet Obstruction (BOO) or urine flow <5 mL/s, as confirmed by uroflowmetry upon suspicion during screening prior to Visit 2
• Urinary incontinence defined as an average of >1 episode/day in the 3-day e-Diary prior to Visit 2 (occasional urge incontinence during daytime or at night on the way to void is not necessarily exclusionary)
• Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic irradiation within the past 6 months prior to Visit 1. Including e.g., transurethral resection for Bladder Outlet Obstruction or Benign Prostatic Hyperplasia, hysterectomy or female incontinence procedures
• Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract infections, interstitial cystitis, bladder-related pain, chronic pelvic pain syndrome, or stone in the bladder or urethra causing symptoms
• A history of cancer with the last date of disease activity/presence of malignancy within the last 12 months prior to Visit 1, except for adequately treated basal cell carcinoma of the skin
• History of any neurological disease affecting bladder function or muscle strength (e.g., Multiple Sclerosis, Parkinson's, spinal cord injury, spina bifida)
• Habitual (fluid intake >3L per day) or psychogenic polydipsia
• Uncontrolled hypertension, as judged by the investigator
• Uncontrolled diabetes mellitus, as judged by the investigator
• Central or nephrogenic diabetes insipidus
• Known history of Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion
• History of gastric retention
• Suspicion or evidence of congestive heart failure, (New York Heart Association (NYHA) class II, III, IV)
• Hyponatraemia:
• Serum sodium level <135 mmol/L at Visit 1(re-tested, with results available within 7 days)
• Serum sodium level <130 mmol/L at Visit 3 (re-tested, with results available within 7 days)
• Use of any prohibited therapy listed below:
• Current or former (within 3 months prior to screening) treatment with any other investigational medicinal product (IMP)
• Unstable electrostimulation or behavioural bladder training program less than 3 months prior to screening (stable electrostimulation or behavioural bladder training program started at least 3 months before screening are acceptable)
• Thiazide diuretics
• Antiarrhythmic agents
• V2-receptor antagonists/agonists (e.g., vaptans/desmopressin, vasopressin)
• Loperamide

Where it is running

• Coastal Clinical Research, an AMR company — Mobile, Alabama, United States
• Clinical Trials Research — Lincoln, California, United States
• Tri Valley Urology Medical Group — Murrieta, California, United States
• San Diego Clinical Trials — San Diego, California, United States
• Advanced Rx Clinical Research Group, Inc. — Westminster, California, United States
• Downtown Women's Health Care — Denver, Colorado, United States
• Genitourinary Surgical Consultants, P.C. — Denver, Colorado, United States
• South Florida Medical Research — Aventura, Florida, United States
• Women's Medical Research Group, LLC — Clearwater, Florida, United States
• Tampa Bay Medical Research, Inc. — Clearwater, Florida, United States
• Clinical Research of South Florida — Coral Gables, Florida, United States
• Avail Clinical Research, LLC — DeLand, Florida, United States
• Finlay Medical Research Corp — Greenacres City, Florida, United States
• Pharmax Research Clinic — Miami, Florida, United States
• Doctors Research Institute Corporation — Miami, Florida, United States
• Sanitas Research — Miami, Florida, United States
• Bayside Clinical Research LLC — New Port Richey, Florida, United States
• Pines Care Research Center, Inc — Pembroke Pines, Florida, United States
• Clinical Research Center of Florida — Pompano Beach, Florida, United States
• Meridien Research, Inc. — St. Petersburg, Florida, United States
• American Health Network of Indiana, LLC — Avon, Indiana, United States
• American Health Network of Indiana, LLC — Greenfield, Indiana, United States
• Bay State Clinical Trials, Inc. — Watertown, Massachusetts, United States
• Beyer Research — Kalamazoo, Michigan, United States
• Achieve Clinical Research, LLC — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.